Enzyvant Logo White Verticle

Patient Focused. Results Driven.

OUR MISSION

DEVELOP

Transformative therapies for rare diseases with high unmet needs.

PURSUE

Innovative partnerships that create new opportunities in the rare disease field.

DELIVER

On our commitment to the patients, families, and communities we serve.

OUR PIPELINE

Enzyvant Pipeline Graphic

RVT-802

Complete DiGeorge Anomaly

Children with complete DiGeorge Anomaly are born without a thymus gland, resulting in primary immunodeficiency. The disease is almost uniformly fatal within the first 24 months of life if untreated.

RVT-801

Farber Disease

Farber disease is an ultra-rare lysosomal storage disease caused by a mutation in both alleles of the ASAH1 gene, resulting in the deficiency of the lysosomal enzyme acid ceramidase.

February 4, 2019

Abstracts highlighting the development of its investigational RVT-801 program and the natural history of Farber disease will be presented in Orlando, Florida, by Enzyvant and its collaborators at the 2019 WORLDSymposiumâ„¢

December 12, 2018

Enzyvant today announced the appointment of George O. Elston as Chief Financial Officer and Head of Corporate Development, further building the capabilities of the company.

July 28, 2018

Enzyvant announced today the appointments of Andrew Dawson to head human resources and Alex Tracy, PhD to lead development and manufacturing, enhancing the overall capabilities of the company

Contact us for more information.